GLP-1SG
GLP-1SG is a glucagon-like peptide-1 receptor agonist studied extensively in metabolic research for its role in glucose homeostasis and appetite regulation signaling. Its extended half-life properties make it a preferred compound for investigating sustained incretin receptor activation in laboratory settings. For research purposes only.
Weekdays before 2PM EST
With Every Batch
Tested in USA
Buy now, pay later with Afterpay, Klarna & Affirm
Research Overview
GLP-1SG is a long-acting GLP-1 receptor agonist featuring a C-18 fatty di-acid chain that enables albumin binding and extends its half-life to approximately 7 days. It is one of the most extensively studied incretin analogs and has become a benchmark compound in metabolic and cardiovascular research.
Mechanism of Action
GLP-1SG binds to the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion and suppressing glucagon release. It delays gastric emptying and activates GLP-1R-expressing neurons in the hypothalamus (arcuate nucleus) to reduce appetite. The C-18 fatty acid modification enables non-covalent albumin binding, dramatically extending circulation half-life. This compound also demonstrates anti-inflammatory effects on vascular endothelium and has shown cardioprotective signals in large-scale clinical research.
Experimental Applications
Research includes GLP-1R signaling pathway studies, dose-response insulin secretion assays, hypothalamic appetite center neuroscience, cardiovascular protection models, hepatic steatosis research, comparative pharmacology against other GLP-1 receptor agonists and dual-agonist compounds, and long-acting peptide pharmacokinetics.
Compound Specifications
| Compound Type | Acylated GLP-1 Receptor Agonist |
| Purity | ≥ 99% |
| Appearance | White lyophilized powder |
| Storage | -20°C long-term; 2-8°C short-term |
| Testing Methods | HPLC, Mass Spectrometry |
| Packaging | Sealed sterile vial |
Molecular Data
| Half-Life | properties, making it a preferred compound in studies examining glucose homeostasis, appetite regulation, and energy metabolism. |
Certificate of Analysis
Lab Testing Notes
Each batch independently verified by HPLC for purity (?99%) and Mass Spectrometry for molecular weight and identity. Acylation integrity confirmed. Full COA provided.
Mechanism of Action
GLP-1SG binds to the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion and suppressing glucagon release. It delays gastric emptying and activates GLP-1R-expressing neurons in the hypothalamus (arcuate nucleus) to reduce appetite. The C-18 fatty acid modification enables non-covalent albumin binding, dramatically extending circulation half-life. This compound also demonstrates anti-inflammatory effects on vascular endothelium and has shown cardioprotective signals in large-scale clinical research.
Experimental Applications
Research includes GLP-1R signaling pathway studies, dose-response insulin secretion assays, hypothalamic appetite center neuroscience, cardiovascular protection models, hepatic steatosis research, comparative pharmacology against other GLP-1 receptor agonists and dual-agonist compounds, and long-acting peptide pharmacokinetics.
Reconstitution Guidelines
Reconstitute with bacteriostatic water. Inject slowly along the inner vial wall. Gently swirl until fully dissolved — do not shake (acylated peptides are sensitive to agitation). Recommended: 1–2 mL per vial. Store at 2–8°C. Use within 30 days.
Related Peptides
Premium research peptides, lab-tested for purity
